Abstracts

GERMINAL CENTER B CELLS INDUCE TFH ACTIVATION AND HIV REPLICATION

Background: T follicular helper cells (TFH) are major sources of HIV replication in people living with HIV infection. T cell activation enhances HIV replication, cytokine secretion including IL-2 and TNF, and expression of several receptors including OX40, CD25, CD69 and 4-1BB. In ex vivo infected tonsils, HIV replication is elevated in activated T cells expressing…

HIGH SUPPRESSION AMONG PLHIV ON DOLUTEGRAVIR WITH VIROLOGICAL FAILURE IN UGANDA

Background: In 2019, WHO recommended dolutegravir (DTG) for first- and second-line antiretroviral therapy (ART) regimens for people living with HIV (PLHIV). Per Uganda treatment guidelines, patients with virologic non-suppression (≥1,000 copies/mL) should receive intensive adherence counseling (IAC) with repeat VL within 6 months. This evaluation analyzed prevalence and factors contributing to suppression following programmatic routine…

EXTRACELLULAR VESICLES IN ALWH PROMOTE CEREBRAL ENDOTHELIAL PROFILES LINKED TO STROKE

Background: The incidence of ischemic stroke in adults living with HIV (ALWH) is three times higher than uninfected adults. Mechanisms underlying this heightened rate of ischemic stroke are poorly understood. Circulating endothelial cell-derived microvesicles (EMVs) have been linked to cerebrovascular events. We have previously reported that EMVs are elevated in ALWH; whether HIV associated EMVs…

ICAM-1 MEDIATES PLASMACYTOID DENDRITIC CELL SENSING OF SARS-CoV-2-INFECTED CELLS

Background: Plasmacytoid dendritic cells (pDCs) are the major producer of type I IFNs (IFN-I), the critically important antiviral cytokines against SARS-CoV-2. Although pDCs can sense cell-free SARS-CoV-2 virions, it is unknown whether they can detect infected cells to produce IFN-I. Since cell-to-cell transmission accounts for 90% of SARS-CoV-2 infections (Zeng et al., 2022), we examined…

BEMNIFOSBUVIR HAS LOW POTENTIAL TO INHIBIT P-gp, BCRP, AND OATP1B1 MEDIATED TRANSPORT

Background: Bemnifosbuvir (BEM, AT-527) is a guanosine nucleotide prodrug candidate for the treatment of COVID-19 and chronic HCV. BEM was identified in vitro as an inhibitor of drug transporters P-glycoprotein, breast cancer resistant protein (BCRP) and organic anion transporting polypeptide 1B1 (OATP1B1). Ph 1 studies in healthy participants were conducted to assess the clinical implications…